Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

101 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real-world data on efficacy and safety of obinutuzumab plus chlorambucil, rituximab plus chlorambucil, and rituximab plus bendamustine in the frontline treatment of chronic lymphocytic leukemia: The GO-CLLEAR Study by the Czech CLL Study Group.
Panovská A, Němcová L, Nekvindová L, Špaček M, Šimkovič M, Papajík T, Brejcha M, Lysák D, Zuchnická J, Novák J, Starostka D, Poul H, Vrbacký F, Vodárek P, Urbanová R, Plevová K, Pospíšilová Š, Mašlejová S, Brychtová Y, Koriťáková E, Smolej L, Doubek M. Panovská A, et al. Among authors: lysak d. Hematol Oncol. 2020 Oct;38(4):509-516. doi: 10.1002/hon.2744. Epub 2020 Jun 1. Hematol Oncol. 2020. PMID: 32400885
Progress in Hematopoietic Stem Cell Transplantation and Cellular Therapies.
Cenariu D, Bumbea H, Colita A, Constantinescu C, Desmirean M, Iluta S, Lysák D, Mussetti A, Tichil I, Tanase A, Tomuleasa C. Cenariu D, et al. Among authors: lysak d. J Clin Med. 2022 Dec 10;11(24):7354. doi: 10.3390/jcm11247354. J Clin Med. 2022. PMID: 36555970 Free PMC article.
The outcome of chronic lymphocytic leukemia patients who relapsed after fludarabine, cyclophosphamide, and rituximab.
Panovská A, Smolej L, Lysák D, Brychtová Y, Šimkovič M, Motyčková M, Vodárek P, Lindtnerová M, Trbušek M, Malčíková J, Pospíšilová Š, Mayer J, Doubek M. Panovská A, et al. Among authors: lysak d. Eur J Haematol. 2013 Jun;90(6):479-85. doi: 10.1111/ejh.12106. Epub 2013 Apr 27. Eur J Haematol. 2013. PMID: 23506191 Clinical Trial.
Chromosome 6q deletion correlates with poor prognosis and low relative expression of FOXO3 in chronic lymphocytic leukemia patients.
Jarosova M, Hruba M, Oltova A, Plevova K, Kruzova L, Kriegova E, Fillerova R, Koritakova E, Doubek M, Lysak D, Prochazka V, Mraz M, Indrak K, Papajik T. Jarosova M, et al. Among authors: lysak d. Am J Hematol. 2017 Oct;92(10):E604-E607. doi: 10.1002/ajh.24852. Epub 2017 Jul 29. Am J Hematol. 2017. PMID: 28699185 Free article. No abstract available.
Single-agent ibrutinib in RESONATE-2™ and RESONATE™ versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia.
Salles G, Bachy E, Smolej L, Simkovic M, Baseggio L, Panovska A, Besson H, Healy N, Garside J, Iraqi W, Diels J, Pick-Lauer C, Spacek M, Urbanova R, Lysak D, Hermans R, Lundbom J, Callet-Bauchu E, Doubek M. Salles G, et al. Among authors: lysak d. Ann Hematol. 2019 Dec;98(12):2749-2760. doi: 10.1007/s00277-019-03830-8. Epub 2019 Nov 19. Ann Hematol. 2019. PMID: 31745601 Free PMC article.
101 results